This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
/ ... / /
/ ... / /

For healthcare professionals only

You are viewing the Novo Nordisk Virtual platform, provided to non-US health care professionals from around the world. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional.

 

This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.

 

This site is not intended to provide medical advice and/or treatment guidance. Novo Nordisk accepts no liability for the accuracy, completeness or use of the information, and disclaims any liability to update the information contained on this site.

I hereby declare I am a non-US health care professional and that I have read and agreed to the terms mentioned above.

Scroll down

Discover how Awiqli® was engineered and understand how its innovative features enable your patients to receive their basal insulin requirements for a full week, in just one injection.

 

 

Help your patients get started

Learn more about starting your insulin-naïve type 2 diabetes patients on once-weekly dosing with Awiqli®
Awiqli® efficacy profile

Learn more about the efficacy data of Awiqli® for your insulin-naïve type 2 diabetes patients

Delivered by a single subcutaneous injection each week, Awiqli® binds strongly and reversibly to albumin.1,2
A slow and steady glucose-lowering effect

*Visual is simplified and does not reflect the real albumin to icodec ratio. There is >2000-fold excess of binding sites in the circulating albumin pool compared with the insulin icodec serum concentration.2

The gradual, continuous release of Awiqli® from albumin results in a slow and steady glucose-lowering effect over one week.1,2

Modelled distribution of glucose-lowering effect of Awiqli® within one-week dosing interval at steady state2

 
Modelled distribution of glucose-lowering effect

If your patients with type 2 diabetes or type 1 diabetes are already on a conventional daily basal insulin therapy, but you think they may benefit from switching to once-weekly dosing with Awiqli®, please speak to your local sales representative or visit the booth.

AUC, area under the curve; GIR, glucose infusion rate; HbA1c, glycated haemoglobin.

1.

Awiqli® (insulin icodec). Summary of Product Characteristics. Novo Nordisk A/S. [June 2024].

2.

Nishimura E, et al. BMJ Open Diab Res Care 2021; 9:e002301.

 

The information contained in this site is intended for healthcare professionals only outside of the United States of America. This site is not intended to provide medical advice and/or treatment guidance. Only a physician can determine whether a specific product is correct for a particular patient. This site is not country-specific and therefore may contain information which is not applicable to your country. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional. Any images shown are models and not real patients.
The Summary of Product Characteristics (SmPC) is based on the EU SmPC as of May 2024. Registration conditions differ internationally. Always refer to the full local SmPC before prescribing.


HQ24AWQ00153, July 2024